Logo

Bio-Rad to Place $250M in Private Notes

May 19, 2009

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories said today that it plans to offer $250 million in a private overseas debt offering to raise funds for working capital, and general corporate purposes, including acquisitions.

The company said that the $250 million aggregate senior subordinated notes will be offered only to qualified institutional buyers and may not be sold inside the United States.

Breaking News
The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.